S-RBD IgG Response After Second Dose of CoronaVac; Prospective Study on Health Workers
DOI:
https://doi.org/10.24293/ijcpml.v29i1.1981Keywords:
CoronaVac, antibody, COVID-19, S-RBD IgG, vaccinationAbstract
COVID-19 infection causes severe acute respiratory syndrome and requires immediate action. Therefore, developing safe vaccine efficacy and new therapies has become a global priority for achieving herd immunity. Vaccination is expected to form specific antibodies against the SARS-CoV-2 spike protein that can neutralize the virus, thus preventing it from binding to its specific receptor (ACE 2 receptor). This study aimed to analyze the kinetics of antibody response to the CoronaVac vaccine after administration of the second dose vaccine. An observational analytic study with a prospective cohort approach was conducted from January to November 2021 at Dr. Soetomo General Academic Hospital, Surabaya. Two hundred fifty specimens from 50 health workers who met the inclusion criteria were measured for S-RBD IgG levels using the indirect chemiluminescence immunoassay method on the Snibe Maglumi® device. The SARS-CoV-2 S-RBD IgG levels were measured five times, such as before vaccination (day 0) and day 14, day 28, month 3, and month 6 after vaccination of the second dose of CoronaVac. The median (min-max) of S-RBD IgG levels before and after vaccination of the second dose on day 14, day 28, month 3, and month 6 were 0.43 (0.43–4.07); 109,25 (30.71–1619,42); 136,46 (19.38–725,28); 26.56 (7.64–158,65); 13.11 (0.59–8666,00) BAU/mL, respectively. There was a significant difference in S-RBD IgG levels at six months post-vaccination between the group with COVID-19 infection and those without COVID-19 disease (p < 0.001). Vaccination of the second dose of CoronaVac resulted in antibody formation; however, there was a trend of decreasing humoral immunity in the 3rd month after the second dose of CoronaVac vaccination in healthy individuals.Downloads
References
Jin Y, Yang H, Ji W, Wu W, Chen S, et al. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses, 2020; 12(4): 1-17.
WHO. COVID-19 Public Health Emergency of International Concern (PHEIC) global research and innovation forum: Towards a research roadmap [Internet]. 2020. Available from: https://www.who.int/
publications/m/item/covid-19-public-health -emergency-of-international-concern-(pheic) -global-research-and-innovation-forum (accessed January 15, 2021).
Kemenkes RI. Nomor HK.01.07/MenKes/413/2020 Tentang Pedoman pencegahan dan pengendalian
Coronavirus Disease 2019 (COVID-19) [Internet]. 2020. Available from: https://peraturan.bpk.go.id/
Home/Details/171647/ (accessed Mar 22, 2021).
KPCPEN. Data vaksinasi COVID-19 Update [Internet]. 2021. Available from: https://covid19.go.id/p/berita/data-vaksinasi-covid-19-update-21-maret-2021 (accessed Jan 15, 2021).
Natarajan H, Crowley AR, Butler SE, Xu S, Weiner JA, et al. SARS-CoV-2 antibody signatures robustly
predict diverse antiviral functions relevant for convalescent plasma therapy. MedRxiv Prepr Serv
Heal Sci, 2020; 9922: 1-27.
Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, et al. A serological assay to detect
SARS-CoV-2 seroconversion in humans. Nat Med, [Internet]. 2020; 26(7): 1033-6.
Nile S, Nile A, Qiu J, Al E. COVID-19: Pathogenesis, cytokine storm, and therapeutic potential of
interferons. Cytokine Growth Factor Rev, 2020; 53: 66-70.
Trougakos IP, Terpos E, Zirou C, Sklirou AD, Apostolakou F, et al. Comparative kinetics of
SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naí¯ve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients. BMC Med, 2021; 19(1): 1-11.
Azkur AK, Akdis M, Azkur D, Sokolowska M, van de Veen W, et al. Immune response to SARS-CoV-2 and
mechanisms of immunopathological changes in COVID-19. Allergy: European Journal of Allergy and
Clinical Immunology, 2020; 75: 1564-81. 10. Liu Z, Xu W, Xia S, Al E. RBD-Fc-based COVID-19
vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. Signal Transduct
Target Ther, 2020; 5: 1-10.
Ali H, Alterki A, Sindhu S, Alahmad B, Hammad M, et al. Robust antibody levels in both diabetic and nondiabetic individuals after BNT162b2 mRNA COVID-19 vaccination. Front Immunol, 2021; 12: 1-9.
Terpos E, Trougakos IP, Karalis V, Ntanasis-Stathopoulos I, Gumeni S, et al. Kinetics of anti-SARS-CoV-2 antibody responses 3 months post-complete vaccination with BNT162B2; A prospective study in 283 health workers. Cells, 2021; 10(8): 1-17.
Abu-Farha M, Al-Mulla F, Thanaraj TA, Kavalakatt S, Ali H, et al. Impact of diabetes in patients diagnosed with COVID-19. Front Immunol, 2020; 11: 1-11.
Blaszczak AM, Jalilvand A, Hsueh WA. Adipocytes, innate immunity and obesity: A mini-review. Front
Immunol, 2021; 12: 1-7.
Hamady A, Lee J, Loboda Z. Waning antibody responses in COVID-19: What can we learn from the
analysis of other Coronaviruses?. Infection, 2021; 50: 11-25.
Hall VJ, Foulkes S, Charlett A, Atti A, Monk EJM, et al. SARS-CoV-2 infection rates of antibody-positive
compared with antibody-negative health-care workers in England: A large, multicentre, prospective
cohort study (SIREN). Lancet, 2021; 397(10283): 1459-69.
Padoan A, Cosma C, Sciacovelli L, Faggian D, Plebani M, et al. Analyti cal performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and antibody kinetics. Clin Chem Lab Med,
; 58(7): 1081-8.
Ontañón J, Blas J, de Cabo C, Santos C, Ruiz-Escribano E, et al. Influence of past infection with SARS-CoV-2 on the response to the BNT162b2 mRNA vaccine in health care workers: Kinetics and durability of the humoral immune response. EBioMedicine, 2021; 73.
Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, et al. Evolution of antibody immunity to SARS-CoV-2. Nature, 2021; 591(7851): 639-44.
Ophinni Y, Hasibuan AS, Widhani A, Maria S, Koesnoe S, et al. COVID-19 vaccines: Current status and
implication for use in Indonesia. Acta Med Indones, 2020; 52(4): 388-412.
Azak E, Karadenizli A, Uzuner H, Karakaya N, Canturk NZ, Hulagu S. Comparison of an inactivated COVID-19 vaccine-induced antibody response with concurrent natural COVID-19 infection. Int J Infect Dis, 2021; 113: 58-64.
Goel R, Painter M, Apostolidis S, Al E. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science, 2021; 374: 1-19.
Lozano-Ojalvo D, Camara C, Lopez-Granados E, Nozal P, del Pino-Molina L, et al. Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered
individuals. Cell Rep, 2021; 36(8): 1-8.
Downloads
Submitted
Accepted
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.